ADRB1 as a potential target for gene therapy of pregnancy induced hypertension and gestational diabetes mellitus

Clin Exp Hypertens. 2011;33(6):422-6. doi: 10.3109/10641963.2010.532265. Epub 2011 Aug 1.

Abstract

Pregnancy-induced hypertension (PIH) and gestational diabetes mellitus (GDM) do not cause any problems with recognition; however, their pathophysiologies are still not explained. Yet many authors suggest that adrenergic β-1 receptor (ADRB1) plays a crucial role. The aim of this study was to evaluate the transcription activity of ADRB1 by using real-time polymerase chain reaction (PCR) in placenta from normal pregnancies and from PIH and GDM. Obtained findings demonstrated a significant increase in ADRB1 mRNA expression in the examined groups in comparison to the control (p = 0.03). Our data indicate a potential perspective of ADRB1 suppression gene therapy in the treatment of PIH and GDM.

MeSH terms

  • Case-Control Studies
  • Diabetes, Gestational / physiopathology
  • Diabetes, Gestational / therapy*
  • Female
  • Genetic Therapy*
  • Humans
  • Hypertension, Pregnancy-Induced / physiopathology
  • Hypertension, Pregnancy-Induced / therapy*
  • Placenta / metabolism
  • Pregnancy
  • Pregnancy Complications / physiopathology
  • Pregnancy Complications / therapy*
  • RNA, Messenger / metabolism
  • Real-Time Polymerase Chain Reaction
  • Receptors, Adrenergic, beta-1 / genetics*
  • Receptors, Adrenergic, beta-1 / metabolism
  • Transcription, Genetic

Substances

  • ADRB1 protein, human
  • RNA, Messenger
  • Receptors, Adrenergic, beta-1